Dendrite Completes Strategic Acquisition of Schwarzeck-Verlag GmbH; Dendrite's German Presence Strengthened by Expanded Solution Offerings and Larger Customer Base.

MORRISTOWN, N.J. -- Dendrite International, Inc. (NASDAQ: DRTE) today announced the completion of its strategic acquisition of Schwarzeck-Verlag GmbH. A subsidiary of Deutscher Aerzte Verlag GmbH based in Munich, Schwarzeck is a leading provider of physician databases, direct marketing services, and sample fulfillment services to pharmaceutical companies in Germany.

The acquisition accelerates Dendrite's expansion in Europe and extends its interactive marketing solutions and services to the German pharmaceutical industry. It creates one of the most diversified German-based suppliers of pharmaceutical-specific services, data, and technology to drug manufacturers in one of the world's largest pharmaceutical markets. By combining Dendrite's sales support solutions with Schwarzeck's marketing support services, the acquisition provides customers with a comprehensive, integrated array of offerings from a single supplier.

"Like our recent purchase of Medical Data Management, our acquisition of Schwarzeck reflects our continued commitment to meet the growing needs of our European customers," said Dendrite President and COO Paul Zaffaroni. "The merger of our two companies not only gives Dendrite a more substantial presence in Germany, but it also provides customers with enhanced solutions for maximizing their promotional initiatives."

Schwarzeck Managing Director Harald Finger added, "Pharmaceutical companies in the region are increasingly partnering with only those vendors that offer a strong combination of technology, support, industry expertise, and local market knowledge. By joining forces with Dendrite, we believe we have a comprehensive portfolio of sales and marketing solutions that will be attractive to the German pharmaceutical industry."

Key Acquisition Elements

Completed on July 13, 2004, the Schwarzeck acquisition provides a compelling value proposition that includes:

--Comprehensive Database Services

Dendrite will add Schwarzeck's physician information sources to its own Pharbase(TM) database services to provide pharmaceutical clients in Germany with one of Europe's richest sources of customer information from which to align sales resources, target and segment customers, conduct sales and marketing initiatives, and measure program results.

--New Interactive Marketing and Fulfillment Services

Pharmaceutical companies in Germany can now benefit from a broad range of direct marketing services--including sample fulfillment, direct mail, and printing services--delivered in a cost-effective and efficient integrated manner by a single provider.

--Senior Leadership and Expertise

Founded in 1972 and employing more than 35 personnel, Schwarzeck brings strong market leadership and experience to complement Dendrite's industry expertise, providing customers with expert guidance, support, and consultancy capabilities.

--Access to New Customers

The Schwarzeck acquisition gives Dendrite a number of new clients in one of the world's largest pharmaceutical markets. Schwarzeck currently serves many of the top pharmaceutical companies in Germany.

Dendrite indicated that in 2003, Schwarzeck reported approximately $4 million in revenue, excluding postage pass-through. Through synergies created by its increased scale and local presence, Dendrite expects the acquisition to be neutral to earnings for the remainder of 2004 and approximately $0.01 accretive in 2005. The transaction, including the assumption of liabilities, is valued at approximately $1 million.

About Schwarzeck-Verlag GmbH

Based in Munich, Schwarzeck-Verlag GmbH (Schwarzeck) is a leading provider of physician databases, interactive marketing, and fulfillment services to the German pharmaceutical industry. For more information, visit www.schwarzeck.de.

About Dendrite

Dendrite develops and delivers solutions that increase the productivity of sales, marketing, and clinical processes for pharmaceutical and other life sciences client. For more information, visit www.dendrite.com.

Note: Dendrite is a registered trademark of Dendrite International, Inc.

The foregoing contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The statements may be identified by such forward-looking terminology as "expect," "believe," "may," "will," "intend," "plan," and similar statements or variations. All "outlook" information constitutes forward-looking statements. Such forward-looking statements are based on our current expectations, estimates, assumptions and projections and involve certain significant risks and uncertainties, including those which may result from our dependence on the pharmaceutical industry; dependence on major customers; economic pressures and legislative and regulatory impact on our customers; fluctuations in quarterly revenues due to lengthy sales and implementation cycles for our products; our fixed expenses in relation to fluctuating revenues; successful and timely development and introduction of new products and versions; rapid technological changes; increased competition; international operations; acquisitions; our ability to attract and retain key personnel; the protection of our proprietary technology; our ability to compete in the Internet-related products and services market; the continued demand for Internet-related products and services; the ability of our third party vendors to respond to technological change; our ability to maintain our relationships with third-party vendors; results from strategic relationships; risks associated with events that may affect the world economy, including terrorism, military action in the Middle East or threat of other hostilities in the Middle East, Asia and other geographical regions; catastrophic events which could negatively affect our information technology infrastructure; difficulties disposing of certain of our facilities; and unexpected changes in accounting regulations, standards or interpretations. Other important factors that should be considered are included in the Company's 10-K, 10-Qs, and other reports filed with the SEC. Actual results may differ materially. The Company assumes no obligation for updating any such forward-looking statements to reflect actual results, changes in assumptions or other changes affecting such forward-looking statements.